East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during
antithrombotic therapies compared with Caucasian patients. As potent P2Y 12 receptor …

Guideline recommendations on the use of dual antiplatelet therapy (DAPT) in patients with
acute coronary syndromes and in those undergoing percutaneous coronary intervention …

The success of trials that have shown net clinical benefits of antithrombotic drugs as well as
the increasing prevalence of cardiovascular diseases in an ageing population have led to …

Background Prolonged dual anti-platelet therapy (DAPT) is intended to reduce ischaemic
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …

More than 4.2 billion inhabitants populate the Asia-Pacific region. Acute coronary syndrome
(ACS) is now a major cause of death and disability in this region with in-hospital mortality …

Background: Patients undergoing percutaneous coronary intervention react differently to
antiplatelet drugs. Those with low responsiveness to clopidogrel have a higher risk of …

Purpose Platelet function test (PFT) results and genotype hold unique prognostic
implications in East Asian patients. The aim of the PTRG-DES (Platelet function and …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is essential after
percutaneous coronary intervention (PCI), while many studies have focused on determining …

Background Although ticagrelor has been well-known to improve clinical outcomes in
patients with acute myocardial infarction (AMI) without increased bleeding risk, its clinical …

Background Prior reports indicate that the effect of P2Y12 inhibitors may be different in East
Asian patients (“East Asian paradox”); therefore, understanding the outcomes associated …